董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William K. Heiden | -- | Chairman of the Board | -- | 未披露 | 未持股 | 2025-12-31 |
| Meenu Chhabra Karson | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Federica O'Brien | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Scott T. Jackson | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Margaret A. Liu | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Karen Jean Ferrante | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Jay Siegel | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-31 |
| Edward Hurwitz | 男 | Independent Director | 61 | 24.13万美元 | 未持股 | 2025-12-31 |
| Eric Risser | 男 | Director, President and Chief Executive Officer | 52 | 未披露 | 未持股 | 2025-12-31 |
| David Stump | 男 | Independent Director | 75 | 22.38万美元 | 未持股 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Beth Smith | -- | Vice President, Controller, Treasurer and Principal Accounting Officer | -- | 未披露 | 未持股 | 2025-12-31 |
| Jeffrey Stuart Peters | -- | Senior Vice President, General Counsel and Corporate Compliance Officer | -- | 未披露 | 未持股 | 2025-12-31 |
| Thomas Spitznagel | -- | Senior Vice President, Technical Operations | -- | 未披露 | 未持股 | 2025-12-31 |
| James Karrels | 男 | Senior Vice President, Chief Financial Officer and Corporate Secretary | 58 | 138.20万美元 | 未持股 | 2025-12-31 |
| Ezio Bonvini | 男 | Senior Vice President, Research and Chief Scientific Officer | 71 | 161.59万美元 | 未持股 | 2025-12-31 |
| Eric Risser | 男 | Director, President and Chief Executive Officer | 52 | 未披露 | 未持股 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- William K. Heiden
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Meenu Chhabra Karson
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Federica O'Brien
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Scott T. Jackson
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Margaret A. Liu
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Karen Jean Ferrante
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Jay Siegel
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Edward Hurwitz
-
Edward Hurwitz，他一直担任公司董事（2018年11月以来）。他曾担任MPM Capital的董事总经理（2017年1月以来），以及Precision BioVentures的董事总经理（2013年创立公司以来）。在加入MPM Capital之前，他从2002年到2014年12月担任Alta Partners的董事。在加入Alta Partners之前，Hurwitz先生从1997年到2002年担任Affymetrix的高级副总裁兼首席财务官。在任职Affymetrix之前，他是Robertson Stephens & Company和Smith Barney Shearson的生物技术研究分析师，也是Cooley Godward LLP的律师。2008年至2014年，他曾担任上市公司Sunesis Pharmaceuticals的董事；2006年至2014年，他曾担任上市公司Cara Therapeutics的董事。Hurwitz先生担任MacroGenics， Inc.和Applied Genetic Technologies Corporation以及几家私人公司的董事会成员。他持有California大学伯克利分校的法学博士和工商管理硕士学位，以及Cornell大学的分子生物学学士学位。
Edward Hurwitz has served as a director of company since November 2018. Mr. Hurwitz has served as a Managing Director at MPM Capital since January 2017 and as Managing Director of Precision BioVentures since he founded the firm in 2013. Prior to joining MPM Capital, Mr. Hurwitz was a Director at Alta Partners from 2002 through December 2014. Prior to joining Alta Partners, Mr. Hurwitz served as Senior Vice President and CFO of Affymetrix from 1997 to 2002. Prior to his service at Affymetrix, Mr. Hurwitz was a biotechnology research analyst for Robertson Stephens&Company and Smith Barney Shearson and a lawyer at Cooley Godward LLP. Mr. Hurwitz previously served as a director of Sunesis Pharmaceuticals, Inc., a publicly held company, from 2008 to 2014 and as a director of Cara Therapeutics, Inc., a publicly held company, from 2006 to 2014. Mr. Hurwitz serves as a member of the board of directors of MacroGenics, Inc. and Applied Genetic Technologies Corporation and several private companies. Mr. Hurwitz earned his J.D. and M.B.A. degrees from the University of California, Berkeley, and his B.A. in molecular biology from Cornell University. - Edward Hurwitz，他一直担任公司董事（2018年11月以来）。他曾担任MPM Capital的董事总经理（2017年1月以来），以及Precision BioVentures的董事总经理（2013年创立公司以来）。在加入MPM Capital之前，他从2002年到2014年12月担任Alta Partners的董事。在加入Alta Partners之前，Hurwitz先生从1997年到2002年担任Affymetrix的高级副总裁兼首席财务官。在任职Affymetrix之前，他是Robertson Stephens & Company和Smith Barney Shearson的生物技术研究分析师，也是Cooley Godward LLP的律师。2008年至2014年，他曾担任上市公司Sunesis Pharmaceuticals的董事；2006年至2014年，他曾担任上市公司Cara Therapeutics的董事。Hurwitz先生担任MacroGenics， Inc.和Applied Genetic Technologies Corporation以及几家私人公司的董事会成员。他持有California大学伯克利分校的法学博士和工商管理硕士学位，以及Cornell大学的分子生物学学士学位。
- Edward Hurwitz has served as a director of company since November 2018. Mr. Hurwitz has served as a Managing Director at MPM Capital since January 2017 and as Managing Director of Precision BioVentures since he founded the firm in 2013. Prior to joining MPM Capital, Mr. Hurwitz was a Director at Alta Partners from 2002 through December 2014. Prior to joining Alta Partners, Mr. Hurwitz served as Senior Vice President and CFO of Affymetrix from 1997 to 2002. Prior to his service at Affymetrix, Mr. Hurwitz was a biotechnology research analyst for Robertson Stephens&Company and Smith Barney Shearson and a lawyer at Cooley Godward LLP. Mr. Hurwitz previously served as a director of Sunesis Pharmaceuticals, Inc., a publicly held company, from 2008 to 2014 and as a director of Cara Therapeutics, Inc., a publicly held company, from 2006 to 2014. Mr. Hurwitz serves as a member of the board of directors of MacroGenics, Inc. and Applied Genetic Technologies Corporation and several private companies. Mr. Hurwitz earned his J.D. and M.B.A. degrees from the University of California, Berkeley, and his B.A. in molecular biology from Cornell University.
- Eric Risser
-
Eric Risser于2009年加入MacroGenics，领导其业务发展工作，并从那时起承担了越来越多的运营和战略责任，最近担任首席运营官。在加入MacroGenics之前，Risser先生曾在Johnson & Johnson担任企业发展高级总监，在那里他领导了多项许可和收购交易。在职业生涯早期，他在投资银行、风险资本和战略咨询等领域担任过各种生命科学职位。他持有Stanford大学的工商管理硕士学位和Yale大学的学士学位。
Eric Risser,joined MacroGenics in 2009 to lead its business development efforts and has assumed roles of increasing operational and strategic responsibility since that time, most recently as Chief Operating Officer. Prior to joining MacroGenics, Mr. Risser worked at Johnson&Johnson as Senior Director in Corporate Development, where he led multiple licensing and acquisition transactions. Earlier in his career, he held a variety of life science roles across investment banking, venture capital, and strategy consulting. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University. - Eric Risser于2009年加入MacroGenics，领导其业务发展工作，并从那时起承担了越来越多的运营和战略责任，最近担任首席运营官。在加入MacroGenics之前，Risser先生曾在Johnson & Johnson担任企业发展高级总监，在那里他领导了多项许可和收购交易。在职业生涯早期，他在投资银行、风险资本和战略咨询等领域担任过各种生命科学职位。他持有Stanford大学的工商管理硕士学位和Yale大学的学士学位。
- Eric Risser,joined MacroGenics in 2009 to lead its business development efforts and has assumed roles of increasing operational and strategic responsibility since that time, most recently as Chief Operating Officer. Prior to joining MacroGenics, Mr. Risser worked at Johnson&Johnson as Senior Director in Corporate Development, where he led multiple licensing and acquisition transactions. Earlier in his career, he held a variety of life science roles across investment banking, venture capital, and strategy consulting. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.
- David Stump
-
David Stump，自2015年9月起担任董事会成员。Stump博士最近担任人类基因组科学研发部门执行副总裁，任职于1999年11月至2012年12月。在加入人类基因组科学公司之前，Stump博士曾在基因泰克担任过各种职务，从1989年到1999年，最近担任临床研究副总裁，并于1996年被任命为基因技术研究员。在加入基因泰克之前，Stump博士是佛蒙特大学的医学和生物化学副教授。Stump博士是Regenxbio，Sunesis Pharmaceuticals，Inc.和MacroGenics，Inc.的董事会成员。Stump博士还是Earlham College的董事会成员。Stump博士获得内科、血液学和内科肿瘤学的董事会认证，是美国内科医师学会和美国心脏协会动脉硬化、血栓形成和血管生物学委员会的研究员。他拥有厄勒姆学院的A.B。和印第安纳大学的医学博士学位，随后在爱荷华大学接受内科、血液学和肿瘤学以及生物化学方面的住院医师和研究金培训，然后在比利时鲁汶大学接受止血和血栓形成方面的进修研究生培训。
David Stump has served as a member of Board since September 2015. Dr. Stump was most recently Executive Vice President, Research and Development at Human Genome Sciences, Inc., serving there from November 1999 until December 2012. Prior to joining Human Genome Sciences, Dr. Stump held various roles at Genentech, Inc., from 1989 to 1999 most recently as Vice President, Clinical Research, and was named a Genentech Fellow in 1996. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump is a member of the Board of Directors of Regenxbio, Inc., Sunesis Pharmaceuticals, Inc. and MacroGenics, Inc. Dr. Stump is also a member of the Board of Trustees of Earlham College. Dr. Stump is board certified in Internal Medicine, Hematology and Medical Oncology, and is a Fellow of the American College of Physicians and the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. He holds an A.B. from Earlham College and an M.D. from Indiana University, followed by residency and fellowship training in internal medicine, hematology and oncology, and biochemistry at the University of Iowa, then by further postgraduate training in hemostasis and thrombosis at the University of Leuven, Belgium. - David Stump，自2015年9月起担任董事会成员。Stump博士最近担任人类基因组科学研发部门执行副总裁，任职于1999年11月至2012年12月。在加入人类基因组科学公司之前，Stump博士曾在基因泰克担任过各种职务，从1989年到1999年，最近担任临床研究副总裁，并于1996年被任命为基因技术研究员。在加入基因泰克之前，Stump博士是佛蒙特大学的医学和生物化学副教授。Stump博士是Regenxbio，Sunesis Pharmaceuticals，Inc.和MacroGenics，Inc.的董事会成员。Stump博士还是Earlham College的董事会成员。Stump博士获得内科、血液学和内科肿瘤学的董事会认证，是美国内科医师学会和美国心脏协会动脉硬化、血栓形成和血管生物学委员会的研究员。他拥有厄勒姆学院的A.B。和印第安纳大学的医学博士学位，随后在爱荷华大学接受内科、血液学和肿瘤学以及生物化学方面的住院医师和研究金培训，然后在比利时鲁汶大学接受止血和血栓形成方面的进修研究生培训。
- David Stump has served as a member of Board since September 2015. Dr. Stump was most recently Executive Vice President, Research and Development at Human Genome Sciences, Inc., serving there from November 1999 until December 2012. Prior to joining Human Genome Sciences, Dr. Stump held various roles at Genentech, Inc., from 1989 to 1999 most recently as Vice President, Clinical Research, and was named a Genentech Fellow in 1996. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump is a member of the Board of Directors of Regenxbio, Inc., Sunesis Pharmaceuticals, Inc. and MacroGenics, Inc. Dr. Stump is also a member of the Board of Trustees of Earlham College. Dr. Stump is board certified in Internal Medicine, Hematology and Medical Oncology, and is a Fellow of the American College of Physicians and the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. He holds an A.B. from Earlham College and an M.D. from Indiana University, followed by residency and fellowship training in internal medicine, hematology and oncology, and biochemistry at the University of Iowa, then by further postgraduate training in hemostasis and thrombosis at the University of Leuven, Belgium.
高管简历
中英对照 | 中文 | 英文- Beth Smith
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jeffrey Stuart Peters
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Thomas Spitznagel
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- James Karrels
James Karrels，高级副总裁、首席财务官兼公司秘书，于2008年5月加入公司，拥有超过20年的财务经验，其中包括behalf of, life sciences companies工作约15年。在加入之前，他在Jazz Pharmaceuticals， Inc.任职，最近担任财务执行董事，负责公司的财务规划和分析以及投资者关系活动。在加入Jazz Pharmaceuticals之前，他在Merrill Lynch的投资银行集团工作了11年，最近担任全球医疗保健集团的董事。他持有Stanford大学的工商管理硕士学位和Notre Dame大学的工商管理硕士学位。
James Karrels, Senior Vice President, Chief Financial Officer and Corporate Secretary, joined in May 2008 and has over 20 years of experience in finance, including approximately 15 years working for, or on behalf of, life sciences companies. Prior to joining, he was at Jazz Pharmaceuticals, Inc., most recently serving as Executive Director of Finance, where he was responsible for the company's financial planning and analysis and investor relations activities. Prior to joining Jazz Pharmaceuticals, Mr. Karrels spent 11 years in the Investment Banking Group at Merrill Lynch, most recently serving as a Director in the Global Healthcare Group. Mr. Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.- James Karrels，高级副总裁、首席财务官兼公司秘书，于2008年5月加入公司，拥有超过20年的财务经验，其中包括behalf of, life sciences companies工作约15年。在加入之前，他在Jazz Pharmaceuticals， Inc.任职，最近担任财务执行董事，负责公司的财务规划和分析以及投资者关系活动。在加入Jazz Pharmaceuticals之前，他在Merrill Lynch的投资银行集团工作了11年，最近担任全球医疗保健集团的董事。他持有Stanford大学的工商管理硕士学位和Notre Dame大学的工商管理硕士学位。
- James Karrels, Senior Vice President, Chief Financial Officer and Corporate Secretary, joined in May 2008 and has over 20 years of experience in finance, including approximately 15 years working for, or on behalf of, life sciences companies. Prior to joining, he was at Jazz Pharmaceuticals, Inc., most recently serving as Executive Director of Finance, where he was responsible for the company's financial planning and analysis and investor relations activities. Prior to joining Jazz Pharmaceuticals, Mr. Karrels spent 11 years in the Investment Banking Group at Merrill Lynch, most recently serving as a Director in the Global Healthcare Group. Mr. Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.
- Ezio Bonvini
Ezio Bonvini担任研究高级副总裁，他于2003年6月加入。从1985年到2003年，他在FDA的生物制品评价和研究中心或CBER工作，负责调节治疗性单克隆抗体和其他蛋白质，最终担任单克隆抗体部门代理副主任和免疫生物学实验室主管。从1982年到1984年，他是美国国立卫生研究院的美国国家癌症研究所客座研究员。他拥有意大利热那亚Scientific Lyceum的理科文凭，热那亚大学（University of Genoa）医学院的硕士和临床血液学专业认证。
Ezio Bonvini, Senior Vice President, Research, joined in June 2003. From 1985 to 2003 Dr. Bonvini was with the FDA in the Center for Biologics Evaluation and Research, or CBER, which is responsible for regulating therapeutic monoclonal antibodies and other proteins, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. From 1982 to 1984 Dr. Bonvini was a Visiting Fellow at the National Cancer Institute at the National Institutes of Health. Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.- Ezio Bonvini担任研究高级副总裁，他于2003年6月加入。从1985年到2003年，他在FDA的生物制品评价和研究中心或CBER工作，负责调节治疗性单克隆抗体和其他蛋白质，最终担任单克隆抗体部门代理副主任和免疫生物学实验室主管。从1982年到1984年，他是美国国立卫生研究院的美国国家癌症研究所客座研究员。他拥有意大利热那亚Scientific Lyceum的理科文凭，热那亚大学（University of Genoa）医学院的硕士和临床血液学专业认证。
- Ezio Bonvini, Senior Vice President, Research, joined in June 2003. From 1985 to 2003 Dr. Bonvini was with the FDA in the Center for Biologics Evaluation and Research, or CBER, which is responsible for regulating therapeutic monoclonal antibodies and other proteins, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. From 1982 to 1984 Dr. Bonvini was a Visiting Fellow at the National Cancer Institute at the National Institutes of Health. Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.
- Eric Risser
Eric Risser于2009年加入MacroGenics，领导其业务发展工作，并从那时起承担了越来越多的运营和战略责任，最近担任首席运营官。在加入MacroGenics之前，Risser先生曾在Johnson & Johnson担任企业发展高级总监，在那里他领导了多项许可和收购交易。在职业生涯早期，他在投资银行、风险资本和战略咨询等领域担任过各种生命科学职位。他持有Stanford大学的工商管理硕士学位和Yale大学的学士学位。
Eric Risser,joined MacroGenics in 2009 to lead its business development efforts and has assumed roles of increasing operational and strategic responsibility since that time, most recently as Chief Operating Officer. Prior to joining MacroGenics, Mr. Risser worked at Johnson&Johnson as Senior Director in Corporate Development, where he led multiple licensing and acquisition transactions. Earlier in his career, he held a variety of life science roles across investment banking, venture capital, and strategy consulting. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.- Eric Risser于2009年加入MacroGenics，领导其业务发展工作，并从那时起承担了越来越多的运营和战略责任，最近担任首席运营官。在加入MacroGenics之前，Risser先生曾在Johnson & Johnson担任企业发展高级总监，在那里他领导了多项许可和收购交易。在职业生涯早期，他在投资银行、风险资本和战略咨询等领域担任过各种生命科学职位。他持有Stanford大学的工商管理硕士学位和Yale大学的学士学位。
- Eric Risser,joined MacroGenics in 2009 to lead its business development efforts and has assumed roles of increasing operational and strategic responsibility since that time, most recently as Chief Operating Officer. Prior to joining MacroGenics, Mr. Risser worked at Johnson&Johnson as Senior Director in Corporate Development, where he led multiple licensing and acquisition transactions. Earlier in his career, he held a variety of life science roles across investment banking, venture capital, and strategy consulting. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.